mitoxantrone liposome

Phase 2Small molecule

TThe First Affiliated Hospital of Soochow University

mitoxantrone liposome is one of 82 small molecule programs targeting Refractory Solid Tumors. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Refractory Solid TumorsNot yet recruiting

Acute Myeloid LeukemiaRecruiting

Refractory Solid TumorsPhase 2

Not yet recruiting

Acute Myeloid LeukemiaPhase 2

Recruiting

Competition

Competitive Landscape

255 competitors in Acute Myeloid Leukemia

#DrugCompanyPhaseTrials

Idamycin

Pfizer

Phase 3

59 2

Xospata

Astellas

Phase 3

24 3

Cerubidine

EEastern Cooperative Oncology Group

Phase 3

42 4

Mylotarg

WWyeth-Lederle Vaccines

Phase 3

38 5

Vanflyta

Daiichi Sankyo

Phase 3

14 6

Neupogen

EEastern Cooperative Oncology Group

Phase 3

31 7

Nexavar

Bayer

Phase 3

12 8

Cellcept

Roche

Phase 3

10 9

Busulfex

Trexall

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2028

Phase 2Not yet recruiting

Refractory Solid Tumors

NCT06761417

Clinical

Trials by Indication[1]

Acute Leukemia1 trial

M-PTCy vs BuCy in Haploidentical HSCT for Acute Leukemia

Unknown status·TThe First Affiliated Hospital of Soochow University·Phase 2/3·NCT05739630·60 enrolled

Refractory Solid Tumors1 trial

A Prospective, Single-arm Clinical Study of Liposomal Mitoxantrone Combination Regimen in the Treatment of Relapsed and Refractory Solid Tumors in Children, Adolescents and Young Adults

Not yet recruiting·—·Phase 2·NCT06761417·49 enrolled

Acute Myeloid Leukemia1 trial

Clinical Study of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

Recruiting·HHui Zeng·Phase 1/2·NCT05522192·70 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for mitoxantrone liposome. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — mitoxantrone liposome compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for mitoxantrone liposome. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Soochow University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TThe First Affiliated Hospital of Soochow University

mitoxantrone liposome

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2028

Trials by Indication[1]

Acute Leukemia1 trial

Refractory Solid Tumors1 trial

Acute Myeloid Leukemia1 trial

References

Drug Info

Quick Facts

Related News